Search This Blog

Thursday, April 9, 2020

ERs quiet during COVID-19: What happens when the patients come back?

Among the unexpected phenomena of the COVID-19 crisis: Emergency departments have seen their volumes plummet.
“The hospitals are eerily quiet, except for COVID-19,” wrote Harlan Krumholz, M.D., a cardiologist and healthcare researcher at Yale University and Yale New Haven Hospital in a column published this week in The New York Times.
That’s been the experience up in Seattle area hospitals which initially expected a “tsunami of emergency department cases,” Gregg Miller, the chief medical officer for Vituity, a physician staffing firm, said recently during the FierceHealthcare Coronavirus Virtual Series. The company works with about 150 emergency departments and 25 hospitalist programs around the country including Dignity Health, Providence St. Joseph Health and Sutter Health systems.
“There has not been a huge surge of emergency department visits with the shutdown of elective surgeries, with the closures of some clinics, with the social distancing that’s been taking place,” Miller said. “There are less and less patients going into the emergency department—thank God, because I can’t imagine working shifts right now what this would be like if we were dealing with our normal volumes on top of what we’re dealing with our COVID patients.”

But what is happening to many of those patients?
It’s a question that hospitals need to be preparing for, said Joanne Roberts, senior vice president and chief value officer at Providence St. Joseph Health System based in Washington.
“If you just look at the big population trends across the country, people are just accessing healthcare less right now probably for lots of reasons: They’re anxious. They want to stay home. They don’t want to be around people. If they don’t have to go to the doctor, they’re not going to go to the doctor,” Roberts said.
In the last week of March, the health system was seeing ED volumes down by more than 40%.
“We assume that people with chronic conditions are probably not getting the level of care they were getting before because it’s not coming into the healthcare system,” Roberts said.
That could be building up to become a later surge among patients with exacerbations in those chronic conditions, she said.
“Whether it’s heart disease or cancer or whatever other chronic problems people may have, we are going to see more acute, exacerbations of those illnesses if we don’t figure out a way to promote access in the next few weeks,” Roberts said. “The country will squeak by for a few weeks but I’m not sure the country could squeak by for multiple months. At that point, we’re going to start seeing more active disease coming into the hospitals.”
For example, one of the more widely reported groups that have raised concerns are patients who have seen surgeries for slow-growing cancers delayed as both health systems and the government have pushed for cancellations of elective procedures to preserve protective equipment and bed capacity.
“Those decisions have been made with a whole lot of thought with specialists, and conferences of specialists, to make sure that nobody is going to be harmed by the delay in the surgeries. For example, any kind of fast-growing cancer is going to get surgery now,” Roberts said. “But all of this stuff is going to back up. It will.”

What should health systems be doing to prepare? Roberts said there is ongoing consideration of having hospitals devoted to non-COVID patients.
“That’s easier said than done. It sounds like a great idea when you say it because of the testing delays we’ve had and the problems getting access to testing, it’s hard to know who is and who isn’t infected with COVID,” she said. “Once we have enough rapid tests that we can look at an entire population of people than we probably can have facilities that only take care of COVID patients or only take care of non-COVID patients. That will probably vary market by market. My guess is that will be one remedy to do that.”
She said once hospitals start feeling confident they have passed their peak of COVID cases, they can begin opening up regular beds to patients of all kinds.
Telehealth may help blunt the problem, Robert said.
“But I think that’s going to be a longer-term proposition,” she said. “Telehealth is exploding right now, but the explosion in telehealth services tends to be very focused on the COVID epidemic itself. So home monitoring around COVID, hospital at home around COVID, using telemedicine in our hospitals is around COVID,” Roberts said. “Once this pandemic has peaked and we’re on the back end of it, I expect we’re going to start by seeing a whole lot more telehealth visits broadly with all kinds of issues. That’s not really the case in any sort of systematic way right now.”
https://www.fiercehealthcare.com/hospitals-health-systems/ers-have-been-quiet-during-covid-19-what-happens-when-patients-come-back

Mount Sinai converts sleep apnea machines into ventilators

So far, Mount Sinai Health System in New York City has had enough ventilators to meet the growing demand due to COVID-19.
But, if the hospital gets overwhelmed, it has an unlikely backup: sleep apnea machines.
More and more hospital systems are looking for ways to shore up their supply of ventilators and have turned to converted sleep apnea machines. Mount Sinai, a system of eight hospitals, has set up its own conversion system to transform a donation of 500 BiPAP machines used to treat sleep apnea to shore up their ventilator capacity.
“It has given us a little reassurance that even as demand goes off and we use more ventilators, this is an arsenal we can tap into to magnify and help our existing fleet,” said Robert Freeman, vice president of clinical innovation at Mount Sinai.
David Rapoport, an expert in sleep medicine and critical care for Mount Sinai, put together a clinical protocol on how to convert sleep apnea machines.

Then, a group of medical students and volunteers turned one of the floors in Mount Sinai’s system into a ventilator assembly area, Freeman said.
“A whole community came together of students, researchers, simulation lab folks to make this happen,” he added.
There are some challenges with converting the devices into makeshift ventilators.
For one, the devices are only supposed to be used for people who don’t need a heavy-duty, hospital-grade ventilator. They are to be employed when a patient is coming off a ventilator but still may need breathing assistance, Freeman said.
The devices, though, can help free up the “powerhouse critical care ventilators for the sickest patients,” Freeman added.
A major issue is also ensuring that the ventilator doesn’t leak any of the virus or aerosolize the virus in a way that puts staff and other patients at risk.
“We wanted to make sure we can get the right filters on there to make sure there was no aerosolization,” Freeman said.
Mount Sinai also had to figure out how to connect the device to the right type of monitor to trigger alarms to alert healthcare workers.
But the hospital system isn’t the only one figuring out how to properly convert sleep apnea machines.
A team of doctors and engineers from the University of California (UC), San Francisco and UC Berkeley have launched a nationwide effort to solicit the donation of home-based, off-the-shelf sleep apnea machines from consumers to their local hospital.
So far, the effort led by the group called the COVID-19 Ventilator Rapid Response Team has gotten between 700 and 1,000 units since the effort was launched last Friday.
The team plans to employ a logistics supplier to distribute the machines to hospitals that need them across the country alongside information on how to convert the machines using simple off-the-shelf parts.
The team’s goal is to get the machines to hospitals in a matter of weeks.
“We are trying to run a test immediately where a hospital calls us up and we will take units from the registry, supply them to a hospital, ship a box of the pats and a video to help people assemble them,” said Bryan Martel, the team organizer and co-founder of Berkeley Engineering and Research Inc.
He added that the group needs input from state and federal governments on which hospitals may need them.
The team is also hoping to get speedy approval from the U.S. Food and Drug Administration, which typically restricts modifying medical devices for a use other than the one they were approved for. The agency has issued new guidance to enable sleep apnea machines used in hospitals to be converted to ventilators.
https://www.fiercehealthcare.com/hospitals-health-systems/mount-sinai-creates-makeshift-assembly-line-to-convert-sleep-apnea

CMS issues infection control guidance for providers struggling with COVID-19

The Trump administration issued a series of new guidance documents focusing on infection control, a major issue for providers treating patients with COVID-19.
The documents released by the Centers for Medicare & Medicaid Services (CMS) also focus on how to ensure infection control for alternative testing and treatment sites some hospitals have had to prop up to handle the outbreak. The agency also put out guidance on telehealth and drive-thru screening infection control.
“The guidance is designed to empower local hospitals and healthcare systems, helping them to rapidly expand their capacity to isolate and treat patients infected with COVID-19 from those who are not,” CMS said in a release Tuesday.

The revised guidance also provides expanded recommendations for screening patients and staff, restricting visitation and how to discharge to other locations.
CMS has suspended routine surveys of healthcare facilities and instead are calling for a major focus on infection control procedures.
A major concern among providers is how to protect their staff from the virus.
CMS also gave a timely update for dialysis facilities on how to provide dialysis at home and how to prop up Special Purpose Renal Dialysis Facilities that can enable facilities to isolate vulnerable or infected people with the virus.
“These temporary changes allow for the establishment of facilities to treat those patients who tested positive for COVID-19 to be treated in separate locations,” the agency said.
Dialysis facilities care for people who are likely immunocompromised and at high risk for COVID-19.
https://www.fiercehealthcare.com/hospitals-health-systems/cms-issues-infection-control-guidance-for-providers-struggling-covid-19

Axon Neuroscience Eyes Promising Peptide Vaccine Against COVID-19

AXON Neuroscience (“Axon”), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases, is developing a promising vaccine candidate against COVID-19.

Axon has over 20 years’ experience in development of safe and immunogenic peptide vaccines. Its well-established scalable technology allowed the company to move quickly in recent weeks to create a novel peptide vaccine in support of the global fight against COVID-19.
Norbert Žilka, Chief Scientific Officer of Axon, said: “We have over sixty scientists with expertise in key disciplines – immunology, pharmacology, structural biology, proteomics, genomics – making Axon ideally placed to deliver a rapid solution for combatting the new coronavirus.”
Axon used its established peptide-based vaccine platform to produce a novel prophylactic COVID-19 vaccine, intended to treat infected patients and protect healthy individuals from infection. Axon’s vaccine contains only selected epitopes capable of inducing desirable T cell and B cell mediated immune responses to prevent interaction of the virus Spike (S) glycoprotein with its target human cells, thus preventing the virus from entering the cells and spreading. This approach is designed to prevent the unwanted serious side effects observed in previous studies of conventional vaccines against SARS-CoV.
The elderly patients most at risk for COVID-19 are prone to develop serious respiratory complications and pneumonia, which might result in permanent lung damage or even death. In general, elderly individuals typically do not respond as well to vaccination, resulting in ordinary vaccinations having a limited effect. Axon has developed innovative proprietary technologies to stimulate the immune systems of elderly people and people with immunodeficiencies in order to produce a high antibody response in these vulnerable populations.
“The human immune system slowly deteriorates with age. This immunosenescence, combined with other comorbidities, makes elderly people highly sensitive to SARS-CoV-2 infections and prone to severe respiratory complications. We believe we have a safe and effective vaccine concept to prevent future outbreaks of COVID-19 and at the same time protect the most vulnerable groups,” said Professor Eva Kontsekova, Immunologist and the Head of Immunotherapy at Axon.
The recent workshop co-chaired by both the European Medicines Agency (EMA) and Food and Drug Administration (FDA) confirmed that an expedited regulatory pathway could be available for well-tested vaccine platforms, such as Axon’s. Data from Axon’s previous Alzheimer’s Disease clinical trials could facilitate a quick move to first-in-human clinical trials with the new COVID-19 vaccine.
Peptide vaccines represent a promising alternative to conventional vaccine approaches, particularly given their speed of development and ease of production. Axon’s longstanding strategic collaboration with the European-based global leader in peptide vaccine manufacturing means that the transfer to GMP production is quick, inexpensive and highly scalable due to the established analytical and manufacturing methods used in Axon’s other development programs.
https://www.biospace.com/article/releases/axon-neuroscience-has-a-promising-peptide-vaccine-against-covid-19-in-development/

All Eyes on Gilead’s Readout of Remdesivir for COVID-19

Gilead Sciences is expected to report data from a clinical trial of its antiviral drug remdesivir against COVID-19 soon. Although the data hasn’t been released yet, analysts are making predictions based on what little they do know.
With a likely vaccine a year out, optimistically, the drug, which was originally developed to treat Ebola, is considered the closest hope for a treatment. It is involved in at least five clinical trials in the U.S. and China.
On April 4, the company announced it had accelerated production of the drug based on overwhelming demand. It currently has 1.5 million individual doses available, enough to treat 140,000 patients. More than 1,700 patients have been treated on an individual compassionate use basis to date.
Reading the tea leaves, analysts with Barclays think there is only a 20% chance that two of the clinical trials being run in China, one in mild-to-moderate cases and another in severely ill, will succeed. Barclays is more focused on what will happen to the company’s stock, even though at this time Gilead indicates it does not plan to charge for the drug. Barclays cites the drug’s complex manufacturing process, which normally takes a year to make, but has been streamlined to about six months, and the difficulties of setting a price and selling a drug for and during a global pandemic.
Barclays also expressed concern that the people being treated by the drug after the disease was well advanced, instead of at a point where it would be more effective.
Other analysts are studying what few moves the company is making publicly to make their predictions. For example, according to clinicaltrials.gov, the remdesivir trial page was updated, changing the size of a study in severe patients from 400 to 2,400, and the moderate patient trial from 600 to 1,600.
RBC believes these numbers include the compassionate use programs and writes, “It is unclear whether all of these patients will be considered in the primary endpoint, but any additional patients should help improve the powering to detect a potential treatment effect (though also indicates they believe more patients would be needed to be able to show a benefit).”
They go on to write, “We believe the changes improve alignment to the latest understanding of COVID-19’s course and should maximize sensitivity to detect any potential treatment effect, though they also imply that—perhaps based on data the company may be observing from ongoing experience with the drug—the magnitude of benefit, if any, is likely to be modest. This aligns with our view that remdesivir, like other COVID-19 drugs in development, would be more likely to have incremental effects in specific populations vs. proving to be a panacea.”
RBC suggests that Gilead’s decision to modify the trial, moving patients on ventilators to a different arm and changing the endpoints, moving to an improvement on a 7-point ordinal clinical assessment scale, means they may be looking for ways to identify if the drug is making more modest positive effects because more obvious ones may not have been possible in the previous design. “Overall, however, these endpoint modifications also underscore our view that based on evolving data to date, both published and followed internally by the company, Gilead may not be expecting to see dramatic benefits.”
Umer Raffat, an analyst at Evercore ISI, however, is more optimistic, writing in a note to investors that “since the Gilead-run trials are open label, the changes made were likely informed by emerging data from these trials. These trials now have LOTS more patients and different endpoints … but allow me to focus on key conclusions…”
The first conclusion of Raffat’s is that the likelihood of success in the moderate-patient trial has increased with the new endpoints, suggesting patients might be recovering more quickly, although it may not have a major impact on how quickly patients are discharged from the hospital, which was a previous primary endpoint, “but remdesivir likely did improve patient status while in hospital.”
The scope of the patients with severe disease has been expanded to include a higher severity level. Raffat interprets this to mean if researchers weren’t seeing any signals in this patient population, they wouldn’t be expanding the criteria to an even higher level. The earlier trial did not include patients on mechanical ventilation, but a “Part B’ has been added to include those patients.
Analysts, of course, are largely focusing on financial up- or downsides for the company. Most of the rest of the world is more interested in whether the drug works. We should get the first sense of that soon.
https://www.biospace.com/article/all-eyes-on-gilead-s-readout-of-remdesivir-for-covid-19/

Glaukos expects Q1 revenues below estimates; withdraws FY20 guidance

Glaukos (NYSE:GKOS) now expects Q1 revenue in the range of $55.0M to $55.3M vs. a consensus of $59.9M.
Due to the continued uncertainties from the impact of COVID-19, Glaukos has withdrawn its previously announced Q1 and FY20 guidance.
GKOS expects the impact of COVID-19 will be significant in the near-term.
https://seekingalpha.com/news/3559698-glaukos-expects-q1-revenues-below-estimates-withdraws-fy20-guidance

Morgan Stanley CEO recovers from coronavirus

Morgan Stanley (MS +5.9%) CEO James Gorman says he has fully recovered from COVID-19, Reuters reports, citing a video sent to the bank’s employees today.
He tested positive for the virus and had been fully cleared by doctors more than a week ago, he said.
Gorman, who started to experience flu-like symptoms in mid-March, is currently working remotely from home.
A Morgan Stanley spokesman said Gorman’s illness wasn’t disclosed publicly because it wasn’t considered material since the illness didn’t incapacitate him.
The spokesman said that Gorman led every one of the bank’s daily operating committee calls since testing positive for COVID-19.
https://seekingalpha.com/news/3559716-morgan-stanley-ceo-recovers-from-coronavirus